Search Result

Results for "

c-MET

" in MedChemExpress (MCE) Product Catalog:

By Targets:	c-Met/HGFR (114) Akt (3) AMPK (1) Anaplastic lymphoma kinase (ALK) (7) Angiotensin Receptor (2) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (30) Autophagy (13) Bacterial (1) c-Kit (7) CDK (1) Cytochrome P450 (1) Discoidin Domain Receptor (2) Drug-Linker Conjugates for ADC (2) EGFR (8) Endogenous Metabolite (1) FGFR (1) FLT3 (8) Glutaminase (2) HDAC (3) HIF/HIF Prolyl-Hydroxylase (1) iGluR (2) Isotope-Labeled Compounds (1) mTOR (1) P-glycoprotein (1) p38 MAPK (3) PARP (1) PDGFR (3) PI3K (1) Polo-like Kinase (PLK) (1) PROTACs (4) RAD51 (2) Raf (2) RET (3) RIP kinase (1) ROS Kinase (9) STAT (1) TAM Receptor (9) Trk Receptor (2) Tyrosinase (2) VEGFR (17)
By Research Areas:	Cancer (122) Infection (1) Inflammation/Immunology (3) Metabolic Disease (5) Neurological Disease (7)
Click Chemistry:	Alkynes (2)

130

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: c-Met/HGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15735

c-Met inhibitor 1 1 Publications Verification	c-Met/HGFR	Cancer
c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.

HY-162679

c-Met degrader-1	c-Met/HGFR Apoptosis	Cancer
c-Met degrader-1 (Compound H11) is an orally active *c-Met* degrader (through the ubiquitin proteasome system). c-Met degrader-1 has anti-hepatocellular carcinoma activity (HCC) and inhibits tumor growth in MHCC97H xenografts. c-Met degrader-1 inhibits HCC cell growth, arrests cell cycle, and induces apoptosis. c-Met degrader-1 may overcome resistance to type Ib inhibitors .

HY-149880

c-Met-IN-18	c-Met/HGFR	Cancer
c-Met-IN-18 is ATP competitive type-III c-MET inhibitor of WT and D1228V mutant c-MET. c-Met-IN-18 has inhibitory for WT/D1228V with an IC₅₀ value of 0.013/0.20 ^e.c-Met-IN-18 can be used for the research of c-MET driven cancers . c-Met-IN-18 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-115937

c-Met-IN-9	c-Met/HGFR Apoptosis	Cancer
c-Met-IN-9, a 4-phenoxypyridine derivative, is a c-Met kinas inhibitor with an IC₅₀ of 12 nM. c-Met-IN-9 induces cells apoptosis, and has antitumor activities .

HY-150582

c-Met-IN-14	c-Met/HGFR c-Kit FLT3 Apoptosis	Cancer
c-Met-IN-14 (compound 26af) is a selective inhibitor of *c-Met* kinase from N-sulfonylamidine-based derivatives, with an IC₅₀ value of 2.89 nM. c-Met-IN-14 shows anticancer activity by blocking phosphorylation of c-Met, and arrests cell cycle at G2/M phase. c-Met-IN-14 induces apoptosis of A549 cells in a dose-dependent manner .

HY-157302

c-Met-IN-21	c-Met/HGFR	Cancer
c-Met-IN-21 (compound 54) is a *c-met* inhibitor with an IC₅₀ value of 0.45? nM, and shows anti-tumor efficacy in vivo .

HY-147694

c-Met-IN-11	c-Met/HGFR VEGFR	Cancer
c-Met-IN-11 (compound 3) is a potent *c-MET* and VEGFR-2 inhibitor, with IC₅₀ values of 41.4 and 71.1 nM, respectively .

HY-157387

c-Met-IN-22	c-Met/HGFR Apoptosis	Cancer
c-Met-IN-22 (compound 51am) is an orally active inhibitor against *c-Met* with an IC₅₀ value of 2.54 nM. c-Met-IN-22 has antiproliferative and antitumor activities. c-Met-IN-22 induces cell apoptosis .

HY-153831

c-Met-IN-17	c-Met/HGFR	Cancer
c-Met-IN-17 is a potent *c-Met* kinase inhibitor with an IC₅₀ of 0.031 μM. c-Met-IN-17 can be used in anticancer research. . c-Met-IN-17 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-162803

c-Met-IN-24	Apoptosis c-Met/HGFR STAT	Cancer
c-Met-IN-24 (compound 3g) is a dual-target inhibitor of STAT-3 ( =4.7 μM) and *c-MET* ( =12.67 μM) with anticancer activity. c-Met-IN-24 arrests the G2/M cell cycle and induces apoptosis in SNB-75 cells. c-Met-IN-24 can be used in the study of central nervous system cancers .

HY-18711

SCR-1481B1 free base METatinib free base; c-MET inhibitor 2 free base	c-Met/HGFR VEGFR	Cancer
SCR-1481B1 free base, also known as Metatinib free base, is a small molecule receptor kinase inhibitor that targets both c-MET and vascular endothelial growth factor receptor 2 (VEGFR2) .

HY-148279

c-Met-IN-15	c-Met/HGFR	Cancer
c-Met-IN-15 (compound S3) is a c-Met kinase inhibitor. c-Met-IN-15 inhibits c-Met kinase activity of 21.1% at the concentration of 10 μM .

HY-147695

c-Met-IN-12	c-Met/HGFR	Cancer
c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II *c-Met* kinase inhibitor, with an IC₅₀ of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy .

HY-161353

c-Met-IN-23	c-Met/HGFR P-glycoprotein	Cancer
c-Met-IN-23 (Compound 12g) is a *c-Met* inhibitor (IC₅₀ = 0.052 μM for c-Met). c-Met-IN-23 also inhibits MDR1 and MRP1/2 pumps in the cancerous HepG2 and BxPC3 cells. c-Met-IN-23 is an anticancer agent .

HY-120908

c-Met-IN-16	c-Met/HGFR	Cancer
c-Met-IN-16 is a *c-Met* inhibitor that can be used for cancer research .

HY-101773

c-Met-IN-2	c-Met/HGFR	Cancer
c-Met-IN-2 is a potent, selective and orally available *c-Met* inhibitor, with an IC₅₀ of 0.6 nM, with antitumor activity.

HY-150004

c-Met/HDAC-IN-3	c-Met/HGFR HDAC Apoptosis	Cancer
c-Met/HDAC-IN-3 (Compound 15f) is a dual *c-Met* and HDAC inhibitor with IC₅₀ values of 12.50 nM and 26.97 nM against c-Met and HDAC1, respectively. c-Met/HDAC-IN-3 induces apoptosis and cause cell cycle arrest in G2/M phase .

HY-101031

c-Met-IN-1	c-Met/HGFR	Cancer
c-met-IN-1 (compound 16) is a potent and selective *c-Met* inhibitor, with IC₅₀ of 1.1 nM, with antitumor activity. .

HY-150576

c-Met-IN-13	c-Met/HGFR	Cancer
c-Met-IN-13 is a potent *c-Met* inhibitor with an IC₅₀ value of 2.43 nM. c-Met-IN-13 shows excellent cytotoxicity for cancer cells. c-Met-IN-13 shows antiproliferative activity in a concentration- and time- dependent manner. c-Met-IN-13 has the potential for the research of cancer .

HY-143462

c-Met/HDAC-IN-2	HDAC c-Met/HGFR Apoptosis	Cancer
c-Met/HDAC-IN-2 is a highly potent *c-Met* and HDAC dual inhibitor with IC₅₀s of 18.49 nM and 5.40 nM for HDAC1 and *c-Met, respectively. c-Met/HDAC-IN-2 has antiproliferative activities against certain cancer cell lines. c-Met/HDAC-IN-2 can cause G2/M-phase arrest and induce apoptosis* in HCT-116. c-Met/HDAC-IN-2 can be used for researching anti-cancer resistance .

HY-162868

c-Met/HDAC-IN-4	c-Met/HGFR HDAC Apoptosis	Cancer
c-Met/HDAC-IN-4 is a dual inhibitor of *c-Met/HDAC. The IC₅₀* value of c-Met/HDAC-IN-4 for c-Met is 28.92 nM. c-Met/HDAC-IN-4 can induce G₀/G₁ phase cell cycle arrest and apoptosis in MDA-MB-231 breast cancer cells, and it inhibits the proliferation and invasion of breast cancer cell lines .

HY-156098

c-Met-IN-19	c-Met/HGFR	Cancer
c-Met-IN-19 (Compound 21j) is a *c-Met* inhibitor (IC₅₀: 1.99 nM). c-Met-IN-19 shows cytotoxicity against A549, HT-29, SGC-7901, MDA-MB-231 cells with IC₅₀s of 0.25, 0.36, 0.98, 0.76 μM .

HY-146274

c-Met-IN-10	c-Met/HGFR Apoptosis	Cancer
c-Met-IN-10 (compound 26a) is a highly potent c-Met kinase inhibitor with an IC₅₀ value of 16 nM. c-Met-IN-10 has inhibitory activity against cancer cells A549, H460 and HT-29 with IC₅₀s of 0.56 ~ 1.59 μM. c-Met-IN-10 suppresses the colony formation on HT-29 cells, induces HT-29 and A549 cells apoptosis, and inhibits A549 cells motility. c-Met-IN-10 can be used for researching anticancer .

HY-18711A

SCR-1481B1 METatinib anhydrous; c-MET inhibitor 2	c-Met/HGFR VEGFR	Cancer
SCR-1481B1 (Metatinib anhydrous) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.

HY-145865

c-Met/MEK1/Flt-3-IN-1	Apoptosis	Cancer
Antiproliferative against-3 (comp 33) shows a prominent activity against Hela (IC₅₀ = 0.21 µM), A549 (IC₅₀ = 0.39 µM), and MCF-7 (IC₅₀ = 0.33 µM), respectively. Antiproliferative against-3 (comp 33) also dose dependently induces apoptosis by arresting A549 cells at G1 phase .

HY-168135

*PROTAC c-Met* degrader-1**	PROTACs c-Met/HGFR	Cancer
PROTAC c-Met degrader-1 (Compound Met-DD4) is an orally active PROTAC degrader for *c-Met* with a DC₅₀ of 6.21 nM. PROTAC c-Met degrader-1 inhibits the proliferation of c-Met-addicted cell MKN-45 with an IC₅₀ of 4.37 nM, and arrests the cell cycle at G0/G1 phase. PROTAC c-Met degrader-1 exhibits antitumor efficacy in MKN-45 xenograft mouse models . (Pink: Ligand for target protein (HY-13404); Blue: Ligand for E3 ligase (HY-W087383); Black: Linker (HY-W074901))

HY-163006

*EGFR/c-Met-IN-1*	EGFR c-Met/HGFR	Cancer
EGFR/c-Met-IN-1 (compound TS-41) is a dual-target inhibitor of *EGFR/c-Met. The IC₅₀ for inhibiting EGFR ^L858R and c-Met* is 68.1 nM and 0.26 nM respectively. . EGFR/c-Met-IN-1 induces apoptosis and cell cycle arrest in A549-P cells, downregulating the phosphorylation of EGFR, c-Met, and downstream AKT. EGFR/c-Met-IN-1 inhibits tumor growth in vitro and in vivo .

HY-161141

*EGFR/c-Met-IN-2*	c-Met/HGFR	Cancer
EGFR/ C-Met-in-2 (Compound H-22) is a dual inhibitor of *EGFR/c-Met. EGFR/c-Met-IN-2 inhibits cell proliferation by arresting G2/M phase. EGFR/c-Met*-IN-2 has antitumor activity .

HY-149674

*VEGFR-2/c-Met-IN-1*	VEGFR	Cancer
VEGFR-2/c-Met-IN-1 is a dual inhibitoe of VEGFR-2 and *c-Met* with *IC₅₀s of 138 nM and 74 nM, respectively. VEGFR-2/c-Met-IN-1 has antitumor activity .*

HY-149675

*VEGFR-2/c-Met-IN-2*	VEGFR c-Met/HGFR	Cancer
VEGFR-2/c-Met-IN-2 (compound 3e) is a *VEGFR-2/c-Met* inhibitor, with IC₅₀ values of 83 and 48 nM, respectively. VEGFR-2/c-Met-IN-2 exhibits cytotoxic activity against HCT-116 cell line (IC₅₀: 3.403 µM) .

HY-164394

EMD 1204831	c-Met/HGFR	Cancer
EMD 1204831 is a potent and highly selective *c-Met* inhibitor which selectively suppresses the c-Met receptor tyrosine kinase activity with an IC₅₀ of 9 nM. EMD 1204831 can be utilized in cancer research .

HY-161372

*PARP1/c-Met-IN-1*	PARP c-Met/HGFR Apoptosis	Cancer
PARP1/c-Met-IN-1 (Compound 16) is a selective dual inhibitor for PARP1 and *c-Met, with IC₅₀s of 3.3 and 32.2 nM, respectively. PARP1/c-Met-IN-1 induces cell apoptosis* and cell cycle arrest in G2/M phase in MDA-MB-231 cells. PARP1/c-Met-IN-1 exhibits antitumor activity in mice .

HY-50683

JNJ-38877605 4 Publications Verification	c-Met/HGFR	Metabolic Disease Cancer
JNJ-38877605 is an orally active ATP-competitive inhibitor of *c-Met* with an IC₅₀ of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases . JNJ-38877605 inhibits c-Met phosphorylation and regulates lipid accumulation. JNJ-38877605 can be used for tumor and metabolic disease reseach .

HY-133083

BAY-474	c-Met/HGFR	Cancer
BAY-474 is a tyrosine-protein kinase *c-Met* inhibitor. BAY-474 acts as an epigenetics probe .

HY-147259

Dalmelitinib	c-Met/HGFR	Cancer
Dalmelitinib is an orally active selective *c-Met* kinase inhibitor (IC₅₀: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC) .

HY-123237

KRC-108	c-Met/HGFR FLT3 Trk Receptor Apoptosis Autophagy	Cancer
KRC-108, an aminopyridine, is an orally active multiple kinase inhibitor with IC₅₀s of 80 nM, 23 nM, 3 nM, 70 nM, 30 nM, 39 nM for *c-Met, c-Met* M1250T, c-Met Y1230D, Ron, Flt3 and TrkA, respectively. KRC-108 induces cell cycle arrest, apoptotic cell death, and autophagy. KRC-108 exhibits anti-tumor activity in vivo in HT29 colorectal cancer, NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice .

HY-147040

ABN401	c-Met/HGFR	Cancer
ABN401 is a highly potent and selective ATP-competitive *c-MET* inhibitor with an IC₅₀ value of 10 nM. ABN401 has cytotoxic activity against MET-addicted cancer cells. ABN401 can inhibit c-MET phosphorylation in tumor tissues. ABN401 can be used for researching anticancer .

HY-116592

SOMCL-863	c-Met/HGFR	Cancer
SOMCL-863 is a selective and orally active *c-Met* inhibitor with antitumor activity in vitro and in vivo. SOMCL-863 can be utilized in cancer research .

HY-18307

SYN1143	c-Met/HGFR	Cancer
SYN1143 is a potent, selective and orally active dual inhibitor of *c-Met/RON, with IC₅₀s of 4 and 9 nM, respectively. SYN1143 has weak inhibitory activity on Lck, Tie2, Src, and BTK* with IC₅₀s ranging from 160 to 710 nM. SYN1143 can be used for the research of cancers that RON and c-Met are activated .

HY-15959

Savolitinib 5+ Cited Publications Volitinib; HMPL-504; AZD-6094	c-Met/HGFR	Cancer
Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable *c-Met* inhibitor with IC₅₀s of 5 nM and 3 nM for c-Met and p-Met, respectively. Savolitinib (AZD-6094) selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. Antineoplastic activity .

HY-123961

SJF-8240	PROTACs c-Met/HGFR	Cancer
SJF-8240 (PROTAC 7) is a proteolysis targeting chimera (PROTAC) degrader. SJF-8240 induces polyubiquitination of *c-Met* and inhibits the proliferation of GTL16 cells (IC₅₀=66.7 nM) .

HY-124267

Zgwatinib SOMG-833	c-Met/HGFR	Cancer
Zgwatinib (SOMG-833) is a potent, selective, and ATP-competitive *c-MET* inhibitor, with an IC₅₀ of 0.93 nM against c-MET, over 10,000-fold more potent compared with 19 tyrosine kinases (including c-MET family members and highly homologous kinases). Zgwatinib potently inhibits c-MET-driven cell proliferation. Zgwatinib as a potential candidate agent for c-MET-driven human cancers research .

HY-14723

AMG-458	c-Met/HGFR	Cancer
AMG-458 is a potent, selective and orally bioavailable *c-Met* inhibitor, with K_i values of 1.2 nM and 2.0 nM for human and mouse c-Met, respectively .

HY-14721

Tepotinib 5 Publications Verification EMD-1214063	c-Met/HGFR Autophagy	Cancer
Tepotinib (EMD-1214063) is an orally active and highly selective, reversible, ATP-competitive *c-Met* inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib inhibits c-Met phosphorylation and induces autophagy. Tepotinib has antitumor effects .

HY-14721A

Tepotinib hydrochloride EMD-1214063 hydrochloride	c-Met/HGFR Autophagy	Cancer
Tepotinib (EMD-1214063) hydrochloride is an orally active and highly selective, reversible, ATP-competitive *c-Met* inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib hydrochloride inhibits c-Met phosphorylation and induces autophagy. Tepotinib hydrochloride has antitumor effects .

HY-116000

Glumetinib 1 Publications Verification Gumarontinib; SCC244	c-Met/HGFR	Cancer
Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive *c-Met* inhibitor with an IC₅₀ of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity .

HY-144394

Antitumor agent-45	Apoptosis c-Met/HGFR	Cancer
Antitumor agent-45 (Compound 21) could induce and stimulate A549 cells apoptosis in G0/G1 and G2/M phase. Antitumor agent-45 (Compound 21) inhibits c-Met expression to regulate the growth of tumor cells .

HY-14721R

Tepotinib (Standard)	c-Met/HGFR Autophagy	Cancer
Tepotinib (Standard) is the analytical standard of Tepotinib. This product is intended for research and analytical applications. Tepotinib (EMD-1214063) is an orally active and highly selective, reversible, ATP-competitive *c-Met* inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib inhibits c-Met phosphorylation. Tepotinib has antitumor effects .

HY-50686

Tivantinib 5+ Cited Publications ARQ 197; (3R,4R)-ARQ 198	c-Met/HGFR Apoptosis	Cancer
Tivantinib is a highly selective *c-Met* tyrosine kinase inhibitor with a K_i of 355 nM.

HY-13404

Capmatinib 10+ Cited Publications INC280; INCB28060	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase .

Cat. No.	Product Name

HY-L188

Anti-Brain Cancer Compound Library

1,546 compounds

Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets.

MCE designs a unique collection of 1,546 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.

HY-L016

Protein Tyrosine Kinase Compound Library

1,140 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,140 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L101

Anti-Liver Cancer Compound Library

1,969 compounds

Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.

Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.

MCE offers a unique collection of 1,969 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P99391

Telisotuzumab ABT-700	Inhibitory Antibodies	Cancer
Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity .

HY-P99196

Ficlatuzumab	c-Met/HGFR	Cancer
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the *HGF/c-Met* signaling pathway, and inhibits *c-Met* receptor-mediated cancer cell proliferation, migration, and invasion .

HY-P99455

Bafisontamab EMB-01	EGFR c-Met/HGFR	Cancer
Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and *cMET* with antitumor activity .

HY-P990432

*Anti-HGFR/c-Met* Antibody**	Inhibitory Antibodies	Inflammation/Immunology

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P99391

Telisotuzumab ABT-700	Classification of Application Fields Disease Research Fields Cancer	Others
Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity .

HY-P99196

Ficlatuzumab	Classification of Application Fields Disease Research Fields Cancer	c-Met/HGFR
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the *HGF/c-Met* signaling pathway, and inhibits *c-Met* receptor-mediated cancer cell proliferation, migration, and invasion .

HY-N6797

Meleagrin	Infection Alkaloids Microorganisms Classification of Application Fields Source classification Disease Research Fields Indole Alkaloids	Bacterial c-Met/HGFR Antibiotic
Meleagrin is a roquefortine C-derived alkaloid produced by fungi of the genus Penicillium and has antimicrobial and anti-proliferative activities. Meleagrin is a class of FabI inhibitor. Meleagrin is a lead *c-Met* inhibitory entity useful for the control of c-Met-dependent metastatic and invasive breast malignancies .

HY-W015309

Decanoic acid	Structural Classification Microorganisms Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Biological Pesticide Research Agricultural Research	iGluR Tyrosinase c-Met/HGFR Glutaminase Endogenous Metabolite
Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of *c-Met* and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-P99455

Bafisontamab EMB-01	Classification of Application Fields Disease Research Fields Cancer	EGFR c-Met/HGFR
Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and *cMET* with antitumor activity .

HY-10261B

(E/Z)-Afatinib (E/Z)-BIBW 2992	Classification of Application Fields Disease Research Fields Cancer	EGFR Apoptosis c-Met/HGFR Akt p38 MAPK Autophagy
(E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells .

HY-W015309R

Decanoic acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	iGluR Tyrosinase c-Met/HGFR Glutaminase
Decanoic acid (Standard) is the analytical standard of Decanoic acid. This product is intended for research and analytical applications. Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

Species:	Human (6) Mouse (1) Cynomolgus (1)
Tag:	His (7) Avi (2) Fc (1)
Source:	HEK293 (8)

Cat. No.	Compare	Product Name	Species	Source

HY-P70714

	HGFR Protein, Human (HEK293, His) Hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; Proto-oncogene c-MET; Scatter factor receptor; SF receptor; Tyrosine-protein kinase MET; MET	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (HEK293, His) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P70715

	HGFR Protein, Human (HEK293, Fc) Hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; Proto-oncogene c-MET; Scatter factor receptor; SF receptor; Tyrosine-protein kinase MET; MET	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (HEK293, Fc) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P78490

	HGFR Protein, Human (HEK293, His-Avi) MET; oncogene MET; HGF R; HGF/SF receptor; AUTS9; cMET; MET (c-MET); RCCP2; SF receptor	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (HEK293, His-Avi) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P701263

	FITC-Labeled HGFR Protein, Human (HEK293, His) MET; AUTS9; HGFR; RCCP2; c-MET	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. FITC-Labeled HGFR Protein, Human (HEK293, His) is the recombinant human-derived FITC-Labeled HGFR protein, expressed by HEK293 , with His labeled tag. The total length of FITC-Labeled HGFR Protein, Human (HEK293, His) is 908 a.a., with molecular weight of 30-40 kDa & 90-100 kDa & 150 kDa, respectively.

HY-P72376

	HGFR Protein, Human (Biotinylated, HEK293, His-Avi) Hepatocyte growth factor receptor; Proto-oncogene c-MET; SF receptor; Tyrosine-protein kinase MET; MET	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.

HY-P703728

	*HGF R/c-MET* Protein, Mouse (HEK293, His)** Hepatocyte growth factor receptor; HGF/SF receptor; Proto-oncogene c-MET; Scatter factor receptor; SF receptor; Tyrosine-protein kinase MET; MET; HGF receptor	Mouse	HEK293

HY-P703800

	*HGF R/c-MET* Protein, Cynomolgus (HEK293, His)**	Cynomolgus	HEK293

HY-P72624

	HGFR Protein, Human (495a.a, HEK293, His) Hepatocyte growth factor receptor; HGF receptor; SF receptor; MET	Human	HEK293
	The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (495a.a, HEK293, His) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-50878S

Crizotinib-d5

Crizotinib-d₅ is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition .

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].

HY-50878AS

Crizotinib-d9 hydrochloride

Crizotinib-d₉ hydrochloride is deuterated labeled Crizotinib hydrochloride (HY-50878A). Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition .

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80219

	*Met (C-Met) Antibody*	WB, ICC/IF, IHC-P, FC	Human
	Met (C-Met) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 156 kDa, targeting to Met (C-Met). It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human.

HY-P80803

	*Phospho-c-Met* (Tyr1349) Antibody** MET; Hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; Proto-oncogene c-MET; Scatter factor receptor; SF receptor; Tyrosine-protein kinase MET	WB, IP	Human
	Phospho-c-Met (Tyr1349) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 156 kDa, targeting to Phospho-c-Met (Tyr1349). It can be used for WB,IP assays with tag free, in the background of Human.